Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Kootenai Health
- Registration Number
- NCT04382625
- Locations
- 🇺🇸
Kootenai Health, Coeur d'Alene, Idaho, United States
A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT04381988
- Locations
- 🇺🇸
Memoral Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States
🇺🇸Memoral Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
Randomised Evaluation of COVID-19 Therapy
- Conditions
- Interventions
- Drug: Lopinavir-RitonavirBiological: Convalescent plasmaBiological: ImmunoglobulinDrug: CorticosteroidDrug: Synthetic neutralising antibodiesDrug: EmpagliflozinDrug: AnakinraDrug: High Dose CorticosteroidDrug: SotrovimabDrug: PaxlovidDrug: Baloxavir MarboxilDrug: HydroxychloroquineDrug: AzithromycinDrug: TocilizumabDrug: AspirinDrug: Dimethyl fumarateDrug: ColchicineDrug: BaricitinibDrug: OseltamivirDrug: Molnupiravir
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 70000
- Registration Number
- NCT04381936
- Locations
- 🇻🇳
Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
🇬🇭Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana
🇮🇳Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2021-07-30
- Target Recruit Count
- 106
- Registration Number
- NCT04380818
- Locations
- 🇪🇸
Hospital Sant Joan de Reus, Reus, Tarragona, Spain
🇪🇸Hospital Del Mar, Barcelona, Spain
🇪🇸Hospital Universitario Madrid Sanchinarro, Madrid, Spain
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT04379492
- Locations
- 🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States
A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers
- Conditions
- Interventions
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2020-05-06
- Lead Sponsor
- Military Hospital of Tunis
- Target Recruit Count
- 660
- Registration Number
- NCT04377646
- Locations
- 🇹🇳
Military Hospital of Tunis, Tunis, Tunisia
Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Baqiyatallah Medical Sciences University
- Target Recruit Count
- 40
- Registration Number
- NCT04376814
- Locations
- 🇮🇷
Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of
Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?
- Conditions
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Megan Landes
- Target Recruit Count
- 13
- Registration Number
- NCT04374942
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 6
- Registration Number
- NCT04373044
- Locations
- 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Texas Cardiac Arrhythmia Research Foundation
- Registration Number
- NCT04371926
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.